Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

Figures & data

Table 1. Incidence of IPD caused by NVTs in some studies mentioned above

		Pre-PCV13 period	Post-PCV13 period
Country	Age	Year	NVT-associated IPD (/100,000)	Year	NVT-associated IPD (/100,000)	Most prevalent serotypes
England^Citation11	All	2012–2013	4.19	2013–2014	5.25	-
	<2 years	2012–2013	10.83	2013–2014	12.03	-
	2–4 years	2012–2013	3.63	2013–2014	4.08	-
England^Citation17	<5 years; >45 years	2013–2014	-	2016–2017	-	8, 12 F, and 9 N
German^Citation15	<16 years	2012–2013	1.1	2015–2016	2.5	-
Gambia^Citation16	2–59 months	Before 2011	14	After 2011	78	-
	2–23 months	2010	49	2011	75	-
Israel^Citation18	All	2009	0.32^a	2015	0.75^b	15B/C, 6 C, 23A, 23B, 24 F

^aOnly the incidence of meningitis (not IPD) is included.

Table 2. Constituent ratio of NVTs in the era of PCV13 in some studies mentioned above

		Pre-PCV13 period		Post-PCV13 period
Country	Age	Year	Non-PCV13-associated IPD	Year	Non-PCV13-associated IPD	Most prevalent serotypes
German^Citation15	<16 years	-	-	2015–2016	84.1%	-
England^Citation11,Citation17,Citation31	All	2008–2010	46.1%	2015–2016	80.6%	8, 12 F, 10A, and 9 N
Belgium^Citation21	Adults	2007–2010	31%	2012–2015	49%	12, 8, and 15 groups
Denmark^Citation23	All	-	-	2014	71%	-
	0–4 years >65 years	- -	- -	2014 2014	91% 73%	- -
India^Citation22	-	2007		2016	21%	10 F, 9 N, 11A, 20, 15B
Hokkaido^Citation26	All	2013	39.7%	2014	75.1%	15A, 23A, 11A, 10A, and 35B
Japan^Citation27	-	2012	51.6%	2014	71.4%	24 F and 15A
Hongkong^Citation28	-	2009–2010	29.4%	2010–2013	56.4%	15B, 15 C, 6 C, and 15A
Taiwan^Citation29	-	2012–2013	17%	2014–2015	44%	15A/F, 15B/C, and 23A
Balearic Islands^Citation22	-	2012–2015	-	2016–2019	58.7%	-
Beijing^Citation30	-	2014–2016	0%	2017–2019	11.7%	15A and 15B

See text for details on local vaccine use.

Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study [J]. Lancet Infect Dis. 2015;15(5):535–43.

 PubMed Web of Science ®Google Scholar

Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study [J]. Lancet Infect Dis. 2018;18(4):441–51.

 PubMed Web of Science ®Google Scholar

Weinberger R, von Kries R, Van Der Linden M, et al. Invasive pneumococcal disease in children under 16 years of age: incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany [J]. Vaccine. 2018;36(4):572–77.

 PubMed Web of Science ®Google Scholar

Mackenzie GA, Hill PC, Jeffries DJ, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study [J]. Lancet Infect Dis. 2016;16(6):703–11.

 PubMed Web of Science ®Google Scholar

Regev-Yochay G, Paran Y, Bishara J, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study [J]. Vaccine. 2015;33(9):1135–42.

 PubMed Web of Science ®Google Scholar

Oligbu G, Collins S, Djennad A, et al. Effect of pneumococcal conjugate vaccines on pneumococcal meningitis, England and Wales, July 1, 2000-June 30, 2016 [J]. Emerg Infect Dis. 2019;25(9):1708–18.

 PubMed Web of Science ®Google Scholar

Henckaerts L, Desmet S, Schalck N, et al. The impact of childhood 13-valent pneumococcal conjugate vaccination on overall invasive pneumococcal disease, including the oldest old [J]. Acta Clin Belg. 2021 Aug;76(4):272–279.

 Web of Science ®Google Scholar

Slotved HC, Dalby T, Hoffmann S. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark [J]. Vaccine. 2016;34:769–74.

 PubMed Web of Science ®Google Scholar

Buades J, Losada I, Gonzalez-Moreno J, et al. Evolution, clinical and microbiological characteristics of invasive pneumococcal disease since the introduction of the pneumococcal conjugate vaccine 13-valent in adults over 18 years old [J]. Vaccines (Basel). 2021;9(2):93. doi:10.3390/vaccines9020093.

 PubMed Web of Science ®Google Scholar

Kawaguchiya M, Urushibara N, Aung MS, et al. Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan [J]. New Microbes New Infect. 2016;9:66–72.

 PubMedGoogle Scholar

Nakano S, Fujisawa T, Ito Y, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012–2014 [J]. Vaccine. 2016;34(1):67–76.

 PubMed Web of Science ®Google Scholar

Ho PL, Chiu SS, Law PY, et al. Increase in the nasopharyngeal carriage of non-vaccine serogroup 15 Streptococcus pneumoniae after introduction of children pneumococcal conjugate vaccination in Hong Kong [J]. Diagn Microbiol Infect Dis. 2015;81(2):145–48.

 PubMed Web of Science ®Google Scholar

Janapatla RP, Su LH, Chen HH, et al. Epidemiology of culture-confirmed infections of Streptococcus pneumoniae (2012–2015) and nasopharyngeal carriage in children and households in Taiwan (2014–2015) [J]. J Med Microbiol. 2017;66(6):729–36.

 PubMed Web of Science ®Google Scholar

Xu Y, Wang Q, Yao K, et al. Clinical characteristics and serotype distribution of invasive pneumococcal disease in pediatric patients from Beijing, China [J]. Eur J Clin Microbiol Infect Dis. 2021; 40(9), 1833–1842.

 PubMed Web of Science ®Google Scholar